Lonza Group stock holds steady as analysts weigh H1 2026
Published on 08/20/2026 at 17:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lonza Group (CH0013841017) stock trades at 619.20 EUR on August 20, 2026, after a 2.93% five-day gain and a 1.96% decline since the start of 2026. The current setup leaves investors focused on the latest half-year backdrop and how it stacks up against the broader contract manufacturing and biosolutions group.
Market context
The clearest live signal is the price itself: 619.20 EUR, with the stock up 2.93% over five trading days but still down 1.96% year to date as of August 20, 2026. That split is a useful read on sentiment, because it shows short-term buying without a full reset in the larger 2026 trend.
Sector comparison data also puts Lonza Group in context versus peers, with the company sitting alongside a market cap of CHF 39.47 billion and an average target price of CHF 681.13 on the same market-data snapshot. The gap between the quoted level and that average target gives the shares a valuation anchor without turning the piece into a prediction.
Half-year lens
On the operational side, the most recent interims remain the key frame of reference for Lonza's business model, especially its biologics manufacturing and contract development work. For investors, the question is not just revenue size but whether margin discipline can keep pace with capital-heavy growth projects.
Peer reporting in the current coverage set helps define that bar: one biosolutions company cited H1 2026 revenue of 116.7 million and gross profit of 72.6 million, while also pointing to revenue growth of 10.5% year over year. It also guided to 2026 organic sales growth of 7% to 8% and an adjusted EBITDA margin at the upper end of 37% to 38%, a combination that highlights how much emphasis the market is placing on profitability as well as growth.
What matters next
Lonza's own investors are likely to watch for the same mix of figures in the next update: revenue growth, margin direction, and cash generation. Those are the numbers that decide whether a company with a CHF 39.47 billion market value can justify a stronger rerating or remain range-bound.
The stock's recent 2.93% five-day move is modest, but it matters because it arrived while the year-to-date return stayed negative at 1.96%. That combination suggests the market is still waiting for a cleaner earnings and outlook story before pushing the shares decisively higher.
Biologics manufacturing
Lonza Group's biologics platform is one of its core products, covering contract development and manufacturing for complex therapies such as monoclonal antibodies and other advanced biologics. The model tends to reward execution quality, plant utilization, and customer pipeline conversion more than simple unit volume.
Stock level
At 619.20 EUR as of August 20, 2026, Lonza Group stock is holding a narrow short-term rebound while the broader 2026 performance remains slightly negative. The level is useful because it combines a current quote with a five-day gain of 2.93% and a year-to-date move of minus 1.96% in one snapshot.
Fact box
Company: Lonza Group
ISIN: CH0013841017
Ticker: LO3
Exchange: Tradegate / European venue
Price (as of August 20, 2026): 619.20 EUR
Market cap: CHF 39.47 billion
Sector / Industry: Biotechnology / Medical research
Index membership: SMI
